Limerick BioPharma Receives $3,050,000 New Financing

  • Feed Type
  • Date
  • Company Name
    Limerick BioPharma
  • Mailing Address
    601 Gateway Blvd. South San Francisco, CA 94080
  • Company Description
    Limerick BioPharma is dedicated to developing compounds that, when used adjunctively with both marketed and investigational drugs, significantly improve the quality of patients’ lives. Our compounds minimize toxic side effects at non-targeted vulnerable organs and tissue while maintaining or enhancing a drug’s desired effects. In the monotherapy setting, we are developing novel compounds that target the treatment of metabolic diseases such as hypercholesteremia and hyperglycemia.
  • Website
  • Transaction Type
    Debt, Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. Amount may include options, warrants or other rights to acquire other securities. SEC regulatory filing-amended.
  • M&A Terms
  • Venture Investor

Trending on Xconomy